阿仑单抗预处理异基因移植后移植物抗宿主病的特征:发生率、器官受累、危险因素与生存
该研究纳入201例接受阿仑单抗为基础的减低强度预处理异基因移植的成人患者,中位随访24个月,分析了急性与慢性GVHD的累积发生率、危险因素及预后。结果显示经典急性GVHD II-IV级累积发生率为34%,晚期急性GVHD为20%,经典慢性GVHD为4%,重叠综合征为7%;既往经典急性GVHD是慢性GVHD的危险因素,而晚发性急性GVHD不是。
要点
- 阿仑单抗-RIC移植后GVHD模式独特:经典急性GVHD II-IV级累积发生率34%,经典慢性GVHD仅4%。
- 无关供者移植是经典急性GVHD的危险因素,但不是晚发性或慢性GVHD的危险因素。
核心结论
- 阿仑单抗-RIC异基因移植后GVHD呈现独特模式,经典急性GVHD较常见而经典慢性GVHD少见。
- 既往经典急性GVHD是后续慢性GVHD的危险因素,晚发性急性GVHD不是。
- 无关供者移植是经典急性GVHD的危险因素,但与晚发性或慢性GVHD无关。
研究设计与样本
- 研究纳入201例连续接受阿仑单抗为基础的减低强度预处理异基因造血干细胞移植的成人患者。
- 中位随访24个月,分析急性与慢性GVHD的累积发生率、器官受累、危险因素及生存。
主要发现
- 经典急性GVHD II-IV级累积发生率为34%,III-IV级为13%。
- 晚期急性GVHD(持续、复发、晚发)II-IV级累积发生率为20%,III-IV级为8%。
- 经典慢性GVHD累积发生率为4%,重叠综合征为7%。
- 无关供者移植是经典急性GVHD的危险因素,但不是晚发性或慢性GVHD的危险因素。
临床怎么用
- 接受阿仑单抗-RIC移植的患者应关注经典急性GVHD的发生,尤其无关供者移植者。
- 既往发生经典急性GVHD的患者需警惕后续慢性GVHD风险。
- 晚发性急性GVHD患者后续慢性GVHD风险未见显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell depletion with alemtuzumab represents an effective form of graft-versus-host disease (GVHD) prophylaxis after allogeneic haematopoietic stem cell transplantation (allo-HSCT); however, little is known regarding the impact of in vivo alemtuzumab on either the incidence or clinical characteristics of acute and chronic GVHD. We therefore studied 201 consecutive adult patients who received an alemtuzumab-based, reduced-intensity conditioned (RIC) allograft. With a median follow-up of 24 months, the cumulative incidence of classic acute and late acute (persistent, recurrent and late onset) GVHD grades II-IV (grades III-IV) was 34% (13%) and 20% (8%) respectively; the cumulative incidence of classic chronic GVHD and overlap syndrome were 4% and 7% respectively. A previous diagnosis of classic acute GVHD is a risk factor for chronic GVHD (hazard ratio 10·91, 95% confidence interval 2·35-50·63, P = 0·0023) while late onset acute GVHD is not a risk factor for later development of chronic GVHD. Unrelated donor transplant is a risk factor for the development of classic acute GVHD but not for late onset or chronic GVHD. In conclusion, this study describes a distinctive pattern of GVHD following alemtuzumab-RIC allografts, identifies the risk factors for GVHD development and provides prognostic information of patients with GVHD.
引用
- Finazzi MC, Boschini C, Craddock C, et al. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. Br J Haematol. 2019. PMID: 31713861. doi:10.1111/bjh.16200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。